Abstract 202P
Background
Interventional therapy is the main treatment for intermediate and advanced hepatocellular carcinoma (HCC) and liver injury is one of the common adverse effects after interventional therapy. This study aimed to compare the liver injury after transcatheter arterial chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) and hepatic arterial infusion chemotherapy (HAIC) combined with ICIs and TKIs for intermediate and advanced HCC.
Methods
We retrospectively enrolled patients with intermediate and advanced HCC who received TACE/HAIC combined with ICIs and TKIs from January 2019 to November 2021, in Nanfang Hospital. The liver function indexs within 1 week before treatment and on the first day after intervention were recorded. The degree of postoperative liver injury was assessed according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0).
Results
82 patients were treated with HAIC combined with ICIs and TKIs and another 77 patients received TACE combined with ICIs and TKIs. There were no significant differences in gender, age, cirrhosis, Child-Pugh grade, ALBI grade and combined ICIs and TKIs regimen at baseline between the two groups. The patients had more advanced tumor stage, heavier tumor load, and poorer liver reserve function in the HAIC group. Patients who underwent HAIC had larger proportion of BCLC stage C HCC(81.7% vs 63.6%,p=0.01),greater percentage of tumor with a maximum diameter greater than or equal to 10 centimeters(64.6% vs 32.5%,p<0.001)than patients in the TACE group. The frequencies of elevated ALT (28.0% vs 63.6%; P<0.001), elevated AST (54.9% vs 85.7%; p<0.001), and hyperbilirubinemia (40.2% vs 55.8%,p=0.049) were significantly lower in the HAIC group than in the TACE group. There were more patients having ALBI score of grade III after therapy in the TACE group than in the HAIC group(16.9% vs 6.1%,p=0.032). The effectiveness of HAIC with ICIs and TKIs were comparable to TACE with ICIs and TKIs.
Conclusions
The incidence of liver injury events was higher in the TACE group than in the HAIC group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract